Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Board Changes

26 Apr 2016 07:00

RNS Number : 2839W
Premier Veterinary Group PLC
26 April 2016
 

 

 

 

 

 

PREMIER VETERINARY GROUP PLC

("PVG" or "the Company")

 

 

BOARD CHANGES

 

London, UK, 26 April 2016 - Premier Veterinary Group plc (LSE: PVG) announces that Juliet Thompson has been appointed as a director and as the independent non-executive Chairman of the Company with effect from 25 April 2016. She succeeds as Chairman Iain Ross who oversaw the successful reverse takeover of the Company into Ark Therapeutics early last year. Iain Ross will remain on the Board as a non-executive director.

Daniel Smith, the Chief Financial Officer, will be leaving the Company in September this year to move to another part of the UK. The Board has commenced a comprehensive recruitment process to identify Daniel's replacement and a further announcement will be made in due course.

Juliet Thompson, a chartered accountant, is currently also a non-executive director of Nexstim, a medical technology company quoted on Nasdaq in Finland and Sweden and was Vice President of Corporate Finance of Precision Ocular, a company focused on retinal diseases, for which she recently led a successful fundraising. Juliet has built a strong track record advising healthcare corporates on strategy and the capital markets. She formerly headed up the healthcare team at Stifel and was a founder of Code Securities, a healthcare investment banking boutique, which became Nomura Code Securities where she was Head of Corporate Finance.

There are no further disclosures required under LR 9.6.13.

Iain Ross, non-executive and former Chairman commented:

"As previously indicated, we have been looking to strengthen our Board with the appointment of an additional independent director. Having been able to attract someone of Juliet's calibre, the Board feels it is appropriate that she joins as our independent non-executive Chairman. She brings extensive City and corporate experience which will be invaluable as we seek to grow the business aggressively."

 For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Daniel Smith, Chief Financial Officer

 

Square1 Consulting Tel: +44 (0)207 929 5599

David Bick/Brian Alexander

 

 

 

Note to Editors:

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary Premier Vet Alliance ("PVA"), include the administration and support of a preventative healthcare program for pets branded "Pet Care Plan"; and the operation of a buying group (the "PVA Buying Group") which offers enhanced discounts to member practices on pharmaceutical and consumable spending.

 

Pet Care Plan is a structured, preventative healthcare program for cats, dogs and rabbits and is available only through veterinary practices. The program is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

Pet Care Plan uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets Pet Care Plan apart is its unique approach of offering an end-to-end solution and support to the practice, which has been proven to work extremely well. PVA works alongside practices to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice performance.

 

The PVA Buying Group, is now the UK's largest veterinary buying group without group interests in veterinary practices or veterinary wholesalers, offering its members the best discounts across the industry on pharmaceutical and consumable spend.

 

For further details: http://www.premiervetalliance.co.uk/

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUVOWRNWASUAR
Date   Source Headline
21st Feb 20117:00 amRNSBoard Change
11th Feb 20117:00 amRNSNotice of Results
8th Feb 20117:00 amRNSDisposal of Majority of Woundcare Business
20th Jan 201112:25 pmRNSHolding(s) in Company
4th Jan 20111:19 pmRNSTotal Voting Rights
16th Dec 20107:00 amRNSChange of Adviser
6th Dec 20109:40 amRNSBlocklisting Interim Review
29th Nov 20101:06 pmRNSHolding(s) in Company
29th Nov 20107:00 amRNSPositive results for pre-clinical product EG013
11th Nov 20107:00 amRNSInterim Management Statement
8th Nov 20102:21 pmRNSHolding(s) in Company
23rd Sep 20104:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20104:35 pmRNSPrice Monitoring Extension
14th Sep 20104:21 pmRNSHolding(s) in Company
14th Sep 20104:19 pmRNSHolding(s) in Company
13th Sep 20103:29 pmRNSDirector/PDMR Shareholding
9th Sep 20107:00 amRNSStrategic Review
31st Aug 201010:33 amRNSTotal Voting Rights
27th Aug 201010:08 amRNSForm 8.5 (EPT/NON-RI)
25th Aug 20107:00 amRNSHalf Yearly Report
20th Aug 20102:27 pmPRNForm 8.3 - Ark Therapeutics Group Plc
19th Aug 201011:35 amRNSForm 8.5 (EPT/NON-RI)
16th Aug 201012:29 pmRNSForm 8.3 - Ark Therapeutics Group plc
16th Aug 20107:00 amRNSForm 8.3 - Ark Therapeutics PLC (Amendment)
13th Aug 20104:24 pmRNSRe EGM
13th Aug 201011:34 amRNSForm 8.5 (EPT/NON-RI)
13th Aug 201011:22 amRNSForm 8.5 (EPT/RI)
13th Aug 201010:30 amRNSForm 8.3 - Ark Therapeutics PLC
11th Aug 201011:35 amRNSForm 8.3 - [Ark Therapeutics Plc]
5th Aug 201012:31 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Aug 20104:41 pmRNSSecond Price Monitoring Extn
4th Aug 20104:35 pmRNSPrice Monitoring Extension
4th Aug 201010:00 amRNSForm 8.3 - Ark Therapeutics Group
3rd Aug 201010:47 amRNSForm 8.3 - Ark Therapeutics
30th Jul 201011:22 amRNSForm 8.3 - Ark Therapeutics Plc
29th Jul 201010:34 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201011:03 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201010:36 amRNSHolding(s) in Company
28th Jul 201010:30 amRNSForm 8.3 - Ark Therapeutics
28th Jul 201010:01 amRNSHolding(s) in Company
26th Jul 20102:57 pmRNSForm 8.3 - [Ark Therapeutics]
26th Jul 20102:41 pmPRNForm 8.3 - ARK THERAPEUTICS
26th Jul 201011:37 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:57 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:15 amRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 20102:34 pmPRNForm 8.3 - Ark Theraputics Plc
22nd Jul 201012:54 pmRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 201011:19 amRNSForm 8.5 (EPT/NON-RI)
22nd Jul 201010:55 amRNSForm 8.3 - Ark Therapeutics Group Plc
21st Jul 20102:41 pmRNSForm 8.3 - Ark Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.